Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer in chemotherapy-naive patients: an Italian analysis of patients’ satisfaction
Abstract Introduction Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favourable impact on patients’ health-related quality of life and pain. Only few papers have in...
Saved in:
Published in | Clinical genitourinary cancer Vol. 15; no. 5; pp. 520 - 525 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.10.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract Introduction Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favourable impact on patients’ health-related quality of life and pain. Only few papers have investigated Patient Reported Outcomes (PROs) in AA treatment for mCRPC. Aim of this study was to investigate patients’ satisfaction in men affected by mCRPC under AA. Materials & Methods Retrospective analysis of a database of consecutive chemonaive patients with progressive mCRPC. Patients were treated with AA until disease progression, death or unacceptable toxicity. Evaluation was performed at baseline and every 4 weeks by means of physical examination and laboratory studies. ECOG score, pain symptoms, treatment-related toxicity, PSA, overall and progression-free survival were recorded. Satisfaction on treatment was investigated at 6 months by means of a 4-point arbitrary scale. Results One-hundred twenty eight patients were enrolled. Patients’ satisfaction on treatment was “greatly improved” in 36.1% of patients and “improved” in 32.4% of them. Patients with higher satisfaction had lower baseline and final PSA values (p<0.05), lower PSA at 12 weeks (p=0,080) and less pain symptoms and lower Brief Pain Inventory score (p=0,001). Satisfaction on treatment was significantly correlated with baseline PSA (p=0,018), presence of pain (p=0,007), duration of ADT >12months (p=0,025), and number of hormonal manipulations (p=0,051). Progression free survival significantly correlated with patient satisfaction (p<0.001). Conclusion AA is safe and well tolerated in chemonaive mCRPC patients, ensures good oncological and PRO outcomes. Patient’s satisfaction is a predictor of progression free survival. |
---|---|
ISSN: | 1558-7673 1938-0682 |
DOI: | 10.1016/j.clgc.2017.04.003 |